Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial

Open Arthritis Journal

Volumn 4, Issue 1, 2011, Pages 1-18

  Specks, Ulrich ^a   Merkel, Peter A ^a   Hoffman, Gary S ^a   Langford, Carol A ^a   Spiera, Robert ^a   Seo, Phil ^a   Kallenberg, Cees G M ^a   St Clair, E William ^a   Ding, Linna ^a   Webber, Lisa ^a   Mokhtarani, Masoud ^a   Tchao, Nadia K ^a   Sayre, Peter ^a   Seyfert Margolis, Vicky ^a   Ikle, David ^a   Brunetta, Paul P ^a   Zhang, David ^a   Sejismundo, Lourdes ^a   Mueller, Mark ^a   Stone, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antineutrophil cytoplasmic antibody (ANCA); B cell depletion; Controlled trial; Granulomatosis with polyangiitis; Immune tolerance; Microscopic polyangiitis; Non inferiority trial; Randomized; Rituximab; Vasculitis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; PLACEBO; PREDNISONE; RITUXIMAB; STEROID;

ADVERSE OUTCOME; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE; CELL COUNT; CEREBROVASCULAR ACCIDENT; DEATH; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLOW UP; HEMORRHAGIC CYSTITIS; HOSPITALIZATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LOW DRUG DOSE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RITUXIMAB IN ANCA ASSOCIATED VASCULITIS TRIAL; STANDARD; STUDY DESIGN; THROMBOCYTHEMIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 82755165229     PISSN: None     EISSN: 18765394     Source Type: Journal    
DOI: 10.2174/1876539401104010001     Document Type: Article

References (43)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: The proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
2. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-53.
3. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-30.
4. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 120(7): 643-9-14.
5. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2: 265-70.
6. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulo-matosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
7. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulo-matosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
8. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
9. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
10. TheWGET ResearchGroup. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.
11. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclopho-sphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996; 124: 477-84.
12. Sneller MC, Hoffman GW, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
13. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666-73.
14. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-803.
15. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54: 1608-18.
16. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35: 100-5.
17. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody--associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-80.
18. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
19. Stevenson HC, Fauci AS. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology 1980; 39: 391-7.
20. Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128: 2453-7.
21. Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987; 79: 1082-90.
22. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836-40.
23. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-8.
24. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-7.
25. Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009; 96: 20-6.
26. Fauci AS, Haynes BF, Katz P. Assessing treatments with cyclopho-sphamide (in comment). Ann Intern Med 1983; 98: 1026-7.
27. Fahey JL, Leonard E, Churg J, Godman G. Wegener's granulo-matosis. Am J Med 1954; 17: 168-79.
28. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44: 912-20.
29. Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010; 5: 445-53.
30. Merkel PA, Cuthbertson DD, Hellmich B, et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoanti body (ANCA)-associated vasculitis. Ann Rheum Dis 2009; 68: 103-6.
31. National cancer institute. Common terminology criteria for adverse events (CTCAE) v.3. Available from. http://ctepcancergov/forms/CTCAEv3pdf
32. Sun J, Fass DN, Hudson JA, Viss MA, et al. Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes. J Immunol Methods 1998; 211: 111-23.
33. Russell KA, Wiegert E, Schroeder DR. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103: 196-203.
34. Lee AS, Finkielman JD, Peikert T, et al. A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. J Immunol Methods 2005; 307: 62-72.
35. Damoiseaux J, Dahnrich C, Rosemann A, et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis 2009; 68: 228-33.
36. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 2004; 43: 13-8.
37. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
38. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9: 842-52.
39. Ishiyama K, Takami A, Okumura H, et al. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy. Int J Hematol 2005; 81: 319-22.
40. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
41. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896-908.
42. Caporali R, Caprioli M, Bobbio-Pallavicini F, Bugatti S, Montecucco C. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009; 8: 591-4.
43. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67:393-8.